Last reviewed · How we verify
TA-1790
At a glance
| Generic name | TA-1790 |
|---|---|
| Sponsor | VIVUS LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating the Effects of Avanafil on Semen Parameters (PHASE4)
- Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy (PHASE3)
- Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D) (PHASE3)
- Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction (PHASE3)
- Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED (PHASE3)
- Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo (PHASE1)
- Assess the Effect of Food on Avanafil Pharmacokinetic (PK), to Compare 2 Oral Formulations of Avanafil,and Investigate Dose Proportionality in Healthy Male Subjects (PHASE1)
- To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TA-1790 CI brief — competitive landscape report
- TA-1790 updates RSS · CI watch RSS
- VIVUS LLC portfolio CI